Civitas Therapeutics has announced the initiation of a Phase 2a clinical trial of its CVT-301 inhaled L-dopa for the treatment of motor fluctuations in patients with Parkinson’s disease. CVT-301 is formulated and delivered using the company’s proprietary Arcus dry powder technology. Development of the product is being funded in part by the Michael J. Fox Foundation for Parkinson’s Research.
Civitas Chief Medical Officer Martin Freed commented, “Consistent with our commitment to rapidly develop important new therapies for patients, we demonstrated pharmacokinetic proof-of-concept for CVT-301 in less than 12 months from launching Civitas and are now initiating this Phase 2a study in Parkinson’s patients. Leveraging the Arcus platform along with the 40 years of existing L-dopa clinical experience we hope to provide Parkinson’s patients with a new therapy enabling improved management of their motor fluctuations.”
Read the Civitas press release.
